Clarient Reports Second Quarter Revenue Up ...( ...),Health

ALISO VIEJO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today reported financial results for the second quarter and six months ended June 30, 2009. Financial results included a 40 percent increase in revenue for the second quarter of 2009 versus the second quarter of 2008, and a 43 percent increase in revenue for this year's first six months versus the first six months of 2008.

Second quarter revenue was $23.7 million, compared to $16.9 million for the same period in 2008. Clarient has now posted 20 consecutive quarters of sequential revenue growth. Revenue for this year's six-month period was $46.9 million, up from $32.8 million in the year-earlier period.

Case volume in the second quarter increased to 33,853 cases, a 29.2 percent increase from the same period in 2008. For the second quarter of 2009, testing volume totaled 236,196, up 21.7 percent from the same period in 2008. The Company's customer base of oncology and pathology practices in the U.S. increased to more than 1,000 active clients at June 30, 2009, from 950 active clients at March 31, 2009.

"Our success in adding new customers, same store sales to current clients, and new product launches continued to drive strong growth in the second quarter, our 20th in a row with sequential growth. These initiatives combined with our new sales force expansion are the foundation for our future success, and should continue to provide a solid growth trajectory throughout the year," said Ron Andrews, Clarient Vi
'/>"/>